Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema.
There has been a rapid expansion in the use of IGIV for an ever-growing number of conditions. It is a product with an excellent safety record without the side effects of steroids or other immunosuppressive agents. There have been numerous recent advances in our understanding of the mechanisms of action of IGIV in many of the conditions for which it is being used, but there is still much to be learned. IGIV has had a major impact in neurology, haematology, immunology, rheumatology and dermatology. The limitations for IGIV are cost of the preparation itself and the logistical problems associated with its administration. Here we describe the published evidence for the use of high-dose IGIV in the dermatological conditions atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis and pretibial myxedema. These conditions have an emerging evidence base for hdIGIV which is relatively small consisting mainly of case reports and small case series. The outcomes in a number of these conditions appear encouraging, but as the reports are likely to reflect a bias for positive results, one must be cautious about drawing firm conclusions.
Jolles
Stephen
S
National Institute for Medical Research, Mill Hill, London and University Hospital of Wales, Cardiff, UK. stephen.jolles@cardiffandvale.wales.nhs.uk
Hughes
Jenny
J
D003876:Dermatitis, Atopic / Q000473:pathology / Q000628:therapy; D006801:Humans; D007116:Immunization, Passive; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D009230:Myxedema / Q000473:pathology / Q000628:therapy; D011565:Psoriasis / Q000473:pathology / Q000628:therapy; D017511:Pyoderma Gangrenosum / Q000473:pathology / Q000628:therapy; D012871:Skin Diseases / Q000473:pathology / Q000628:therapy*; D014581:Urticaria / Q000473:pathology / Q000628:therapy
D016756:Immunoglobulins, Intravenous